Epigen Biosciences, Inc.
San Diego, CA · Biotech · Private
Selective sigma-1 receptor (S1R) small molecule ligands (EPGN2544, EPGN2665) for treatment of neurodegenerative diseases
epigenbiosciences.com →- Grants
- $21M
- 29 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 11
- 6 granted · 5 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Development of novel agents for the treatment of renal fibrosis | $835,306 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel integrin inhibitors for kidney fibrosis | $228,661 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of novel agents for the treatment of renal fibrosis adminstrative supplement | $2,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel therapy for Fragile X syndrome | $399,938 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Treatment for Traumatic Brain Injury | $417,267 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel therapy for Fragile X syndrome | $117,346 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis | $2,998,612 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Novel therapy for Fragile X syndrome | $317,514 | |
| Federal grant | Department of Health and Human Services · Phase I · New Approach to Atopic Dermatitis | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Assessment of LPA1R antagonists in animal models of NASH | $298,946 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis | $999,274 | |
| Federal grant | Department of Health and Human Services · Phase II · Lead optimization and development of novel targeted small molecule therapeutics for Alzheimers disease | $2,171,366 | |
| Federal grant | Department of Health and Human Services · Phase I · Therapeutic in Situ Analgesic Implant for improved Oral-Facial Post-Operative Pain Outcomes | $390,335 | |
| Federal grant | Department of Health and Human Services · Phase II · Lead optimization and development of novel targeted small molecule therapeutics for Alzheimers disease | $1,322,759 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel agents for idiopathic pulmonary fibrosis | $299,983 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis | $999,838 | |
| Federal grant | Department of Health and Human Services · Phase I · Assessment of a selective kinase inhibitor in pre-clinical models of NASH | $375,033 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel therapy for Fragile X syndrome | $998,958 | |
| Federal grant | Department of Health and Human Services · Phase II · Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy | $1,035,811 | |
| Federal grant | Department of Health and Human Services · Phase I · Evaluation of Alzheimers disease experimental small molecule therapeutics in the models of Amyotrophic lateral sclerosis | $449,984 | |
| Federal grant | Department of Health and Human Services · Phase II · Administrative supplement for Novel therapy for Fragile X syndrome | $50,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Lead candidate identification of LPAR1 antagonists for therapeutic application in NASH | $397,398 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel therapy for Fragile X syndrome | $1,157,216 | |
| Federal grant | Department of Health and Human Services · Phase II · Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy | $990,691 | |
| Federal grant | Department of Health and Human Services · Phase I · New Therapy for the Treatment of Primary Biliary Cholangitis. | $448,110 | |
| Federal grant | Department of Health and Human Services · Phase II · Candidate selection of a LPAR1 antagonist for therapeutic application in NASH | $971,732 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Product Formulation toModulate Alpha7 Nicotinic Receptors for Therapy in Stroke Recovery | $550,864 | |
| Federal grant | Department of Health and Human Services · Phase II · Candidate selection of a LPAR1 antagonist for therapeutic application in NASH | $1,041,548 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Methods for Nicotinic Receptor Modulation in the Treatment of Post-Operative Pain | $349,999 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1692 | MicroMGx, Inc. | — | — |
| 1693 | AEON RESPIRE, INC. | — | — |
| 1694 | NEMUCORE MEDICAL INNOVATIONS, INC. | — | — |
| 1695 | Epigen Biosciences, Inc. | — | — |
| 1696 | ONECYTE BIOTECHNOLOGIES, INC. | — | — |
| 1697 | Igenica | — | — |
| 1698 | ZabBio, Inc. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Pyrimidine And Pyridine Amine Compounds And Usage Thereof In Disease Treatmentgranted
- Pyrimidine And Pyridine Amine Compounds And Usage Thereof In Disease Treatmentgranted
- Heterocyclic Compounds Useful In The Treatment Of Diseaseapplication
- Heterocyclic Compounds Useful In The Treatment Of Diseasegranted
- Heterocyclic Compounds Useful In The Treatment Of Diseasegranted
- Heterocyclic Compounds Useful In The Treatment of Diseasegranted
- Heterocyclic Compounds Useful In The Treatment Of Diseasegranted
- Methods and Compositions Useful in the Treatment of Diseaseapplication
- Pyrimidine And Pyridine Amine Compounds And Usage Thereof In Disease Treatmentapplication
- Heterocyclic Compounds Useful In The Treatment Of Diseaseapplication
- Heterocyclic Compounds Useful In The Treatment Of Diseaseapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.